Literature DB >> 7951341

Initial chemotherapy for stage II testicular non-seminoma.

A Horwich1, S Stenning.   

Abstract

A retrospective survival analysis was performed on 287 patients treated with chemotherapy following orchidectomy for stage II testicular non-seminoma between 1982 and 1986 at a number of centres in the United Kingdom and 1 centre in Norway. A total of 80 patients had lymphadenectomy for a residual mass after chemotherapy. In 17 of these cases the histology was undifferentiated malignancy, in 44 it was differentiated teratoma, in 18 there was necrosis only and in 1 case histology was unknown. The overall survival in 47 patients with initial stage IIA disease (nodes measuring < 2 cm in transverse diameter) was 98% [95% confidence interval (CI), 96%-100%] at 3 years. In 175 patients with stage IIB disease (nodal diameter, 2-5 cm) the 3-year survival was 96% (95% CI, 93%-99%) and in 65 patients with stage IIC disease (nodal diameter, > 5 cm) it was 84% (95% CI, 75%-93%). In stage IIA and stage IIB disease this approach leads to survival equivalent to that obtained with the approach of initial retroperitoneal lymph-node dissection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7951341     DOI: 10.1007/BF00192276

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  13 in total

1.  Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer?

Authors:  J P Richie; P W Kantoff
Journal:  J Clin Oncol       Date:  1991-08       Impact factor: 44.544

2.  Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol.

Authors:  L H Einhorn; S D Williams; P J Loehrer; R Birch; R Drasga; G Omura; F A Greco
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

3.  Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation.

Authors:  M A Jewett; Y S Kong; S D Goldberg; J F Sturgeon; G M Thomas; R E Alison; M K Gospodarowicz
Journal:  J Urol       Date:  1988-06       Impact factor: 7.450

4.  Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer.

Authors:  J P Donohue; R G Rowland; K Kopecky; C P Steidle; G Geier; K G Ney; L Einhorn; S Williams; P Loehrer
Journal:  J Urol       Date:  1987-06       Impact factor: 7.450

5.  Surveillance after orchiectomy for stage I seminoma of the testis.

Authors:  M J Peckham; C R Hamilton; A Horwich; W F Hendry
Journal:  Br J Urol       Date:  1987-04

6.  Increasing the dose intensity of chemotherapy in poor-prognosis metastatic non-seminoma.

Authors:  A Horwich; C Wilson; P Cornes; J Gildersleve; D Dearnaley
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

7.  A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

Authors:  G J Bosl; N L Geller; D Bajorin; S P Leitner; A Yagoda; R B Golbey; H Scher; N J Vogelzang; J Auman; R Carey
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

8.  Comparison between clinical and pathological staging in low stage nonseminomatous germ cell testicular tumors.

Authors:  G Pizzocaro; N Nicolai; R Salvioni; L Piva; M Faustini; F Zanoni; A Milani
Journal:  J Urol       Date:  1992-07       Impact factor: 7.450

9.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.

Authors:  S D Williams; R Birch; L H Einhorn; L Irwin; F A Greco; P J Loehrer
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

10.  Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients.

Authors:  C J Logothetis; D A Swanson; F Dexeus; C Chong; S Ogden; A G Ayala; A C von Eschenbach; D E Johnson; M L Samuels
Journal:  J Clin Oncol       Date:  1987-06       Impact factor: 44.544

View more
  2 in total

1.  Canadian consensus guidelines for the management of testicular germ cell cancer.

Authors:  Lori Wood; Christian Kollmannsberger; Michael Jewett; Peter Chung; Sebastian Hotte; Martin O'Malley; Joan Sweet; Lynn Anson-Cartwright; Eric Winquist; Scott North; Scott Tyldesley; Jeremy Sturgeon; Mary Gospodarowicz; Roanne Segal; Tina Cheng; Peter Venner; Malcolm Moore; Peter Albers; Robert Huddart; Craig Nichols; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

Review 2.  Testicular germ cell tumors: pathogenesis, diagnosis and treatment.

Authors:  Christian Winter; Peter Albers
Journal:  Nat Rev Endocrinol       Date:  2010-11-30       Impact factor: 43.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.